AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 268: E1070-E1076, 1995;
0193-1849/95 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsumoto, Y.
Right arrow Articles by Yamazaki, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsumoto, Y.
Right arrow Articles by Yamazaki, N.

AJP - Endocrinology and Metabolism, Vol 268, Issue 6 E1070-E1076, Copyright © 1995 by American Physiological Society

ARTICLES

Creatine kinase kinetics in diabetic cardiomyopathy

Y. Matsumoto, M. Kaneko, A. Kobayashi, Y. Fujise and N. Yamazaki
Third Department of Internal Medicine and Chemistry, Hamamatsu University School of Medicine, Japan.

One feature of the diabetic cardiomyopathy is the appearance of contractile dysfunction as the workload increases. We hypothesized that this resulted from an impaired creatine kinase/phosphocreatine system and therefore examined the creatine kinase kinetics at both low and high workloads. Creatine kinase flux (by 31P nuclear magnetic resonance saturation transfer method), cardiac performance, and oxygen consumption were measured in control and streptozotocin-induced diabetic rat hearts. Creatine kinase flux was inhibited by iodoacetamide in control hearts to confirm the role of the creatine kinase/phosphocreatine system in cardiac performance. In diabetic hearts, 1) the contractile dysfunction became apparent only at high workloads, 2) the ATP synthesis rate was not significantly different from control hearts, 3) the creatine kinase flux was reduced by 30.8% (257.5 +/- 7.7 mumol.g wet wt-1.min-1 in control vs. 178.3 +/- 9.4 in diabetes, P < 0.001), and 4) the creatine kinase flux did not increase as the workload increased. In control hearts, 5) iodoacetamide inhibited the creatine kinase flux to the same degree as that in diabetic hearts, and 6) the contractile dysfunction was not as severe as that observed in diabetic hearts. These results suggest that the impaired creatine kinase/phosphocreatine system is, at least in part, responsible for the contractile dysfunction in the diabetic cardiomyopathy.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
R. Ramasamy, J. A. Payne, J. Whang, S. R. Bergmann, and S. Schaefer
Protection of ischemic myocardium in diabetics by inhibition of electroneutral Na+-K+-2Cl{-} cotransporter
Am J Physiol Heart Circ Physiol, August 1, 2001; 281(2): H515 - H522.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
M. Wyss and R. Kaddurah-Daouk
Creatine and Creatinine Metabolism
Physiol Rev, July 1, 2000; 80(3): 1107 - 1213.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online